Member Info for Steadydanny

Hi HBD.
Yes it was a question for mafutas opinion re the 1802 US properly granting today so I'm iof the assumption a RNS would be required today/tomorrow (given GMT).
My point was that yesterday's update said two grants had been approved as below...
• Two new US patents granted (January and September 2021) strengthening patent protection, which is now in place across all major territories
But this from earlier RNS..
further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme").

The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.
The devil is in the detail re precise wording of approval and grant. It officially grants today! Is it a genuine mistake? Unusual for the sareum board to make one on a RNS.
Anyway that was lost due to a posts being removed. Best Steadydanny

Fade its because its part of our strategy
From our website
Our Strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

There's a handy chart on the website also that shows where our drugs are. You will note where 1801 is......

Absolutely agree. Substantial funding following the Edison report that as reported will fund ongoing progress. They will have seen the potential after undertaking dd.
Also dosnt stop 'bids' for licenses by any means...the investments show confidence and any interested 'other parties' will have to pay appropriately....we are in a cracking position.

That's what I'm thinking jonners. It sounds like a nod to submarine patent and multiple licenses and GSK will be at the front of the que.

Just like to mention that the results take us upto June 30th.
Post the 30th of June we have realised a further £2m in subscriptions and £180k in exercised warrants.
Not too shabby by any means given the £2.37m raised prior to said date.
Also as all can see the positive updates that have followed officially via RNS and the cracking find re the 737 that has yet to be followed up by the board. They normally update anything that Sierra are doing with 737...so that's another update incoming...and the improved 1802 US granting on 26th October.
It's beginning to feel alot like Christmas.....coming early? :-)
Best regards Steadydanny

Hi Green. There has been a bit of consternation here recently.
If you have a bit of time on your hands I would personally, aka, my opinion look up cytokine storms. Causation and treatment. Cytosine and tyrosine (now called thymine) displaced with uracil are a starter.
And sareums ipr.
I am reticent to make my opinion here public re our potential for what I believe is the real deal.
But time will tell. Indicators are supportive.

How we work

Sareum operates a lean business model to deliver the most productive return for our research spend. This is accomplished by:

maintaining a low cost base by having a small in-house teamundertaking laboratory-based research using external providersengaging in research and development collaborations to share costs and access expertisehaving access to a worldwide network of expert research providers to progress programmespursuing multiple drug development programmes to reduce the risk to the company

The goals are to build value by progressing our research programmes through early clinical development and generate revenues by licensing them to pharmaceutical company partners.

Find out more about our partners and current collaborations.

Green. Hope that assists you on your query just before trading update on Monday and improved 1802 grant the day after...and submarine patent...so why your point re number of employees?
A board of conductors utilise various musicians to make a harmony sing.
Get it yet?

Green. You might do well to look at Sareums website. And then read the RNSs going back to 2010.

Exactly HBD. And the 'How we work' tab is relevant.

Hi Mafuta. Re the trading update maybe being a normal formality as someone has mentioned, which they normally are, I still hark back to the 25th May RNS

The Company looks forward to providing a more comprehensive business update at the time of the Full-year Results, expected in October 2021.

I personally think they will light the touch paper on Monday which within the rns may have something of a partial point of further intrigue, 1802 improvement approved rns Tuesday or Wednesday given time variants between UK and US.
I think we have as a bb by the diligent posters re all of our ipr potential and forward investment strategy been seen by those who want in but tried to reduce the sp. I saw the spread at one point on Friday over 6%!
Anyways things are happening.
Lots of news potential.
I think our board are brilliant.
This is not a run of the mill company.
I apologise re the T discussion last night. Just feel this bb with the great posters here don't need to be advised to sign up elsewhere. If it ain't broke why fix it?

Hi mafuta. My questions will be considered post Monday update. Effectively we only are able to answer questions following approved released information.

re the 2nd November live presentation?
I appreciate they add this
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 a.m. the day before the meeting or at any time during the live presentation. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. 
The last part re information already disclosed to the market. Will Monday's trading update reveal more info that might allow a question or two beyond confines of disclosed information so far?
Personally I would like to ask if the submarine patent will 'submerge' after general viewing of its potential fundamentals that would mean we have protection of any future competitors developing said so far released info ( but is it official, ie RNS requirement to be official?) which would mean we take royalties or license agreements.
Also like to ask about the relevance and specifics of the other contributors named and collaborations as that I'm assuming would mean they are part of the payroll so would be disclosed as partners or that they are non fee participants with the patent application and thus royalty dependants so not necessaryto reveal reasons?
Just a muse.
Best regards Steadydanny

Ahfam. I suspect the questions put forward for the investor discussion if put now will be irrelevant following 25th October update. They specifically say they can respond re previous posted information. The may rns indicates a more informative update.
What I think that has been non discussed today post RNS is what question anyone would put forward.
I've a few. But love to hear others.

Hi Afham. Just to note that the first HNWI exercised their 5p warrants on 14th July. So another £180k in the bank.
Re the 737 link just posted (great find) I have noticed that Sareum have regularly been dropping 737 into updates. Not just a sentence but a bit more......they did mention that they were positive about Sierras new appointment and hoped to see 737 on his radar re pipeline.
Also worth noting the recent news re treatments our govt have signed up for and the also relatively recent collaboration between AZ and Sierra.
Also see the RNS re 25th October.....not forgetting our US Patent improvement grants the day after...so 'assuming' a RNS to confirm that and maybe a bit more info.
So much ticking along.

Blimey I think this green bitcoin is catching on!!

I apologise. Just winds me up with some of the defamatory posts that have no tangible response .

The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.
So really love some thoughts re submarine patent. Have we got the patent for something that will be exponential in all big pharmas wanting a piece of it and to develop at their own cost and direction? Which we would act as advisors but due to NDAs cannot reveal their direction? But take multiple licences and royalties?
This was a previous post of mine. Then raised a discussion re the submarine patent. Check my posts.
Great discussions.
Just check out the date and points.
Noticed some covert lth are breaking ground.
Appreciate that. About time.

26th October.

It's about what is in their pipeline or future pipeline.

Based on ? Radio silence on Sierra Oncology and sra 737 re sareum and a certain UK based Cancer research charity.